Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage and impaired clearance occur early and are difficult to reverse. Their findings underscore that tackling amyloid alone may not be enough to restore brain function, urging a broader approach to treatment.
Not to mention that the original research on amyloid beta has now been proven to have been “doctored” and quite conclusively at that, why they continue to pursue drugs that clear it behooves me. Literally throwing billions of dollars into trash.
The original study was doctored, but plenty of others with similar results weren’t.